Detail akcie Xoma Royalty Corporation online

Business Summary: XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, XOMA Royalty Corp revenues increased 94% to $38.4M. Net income applicable to common stockholders totaled $15.2M vs. loss of $14M. Revenues reflect Income from purchased receivables under increase of 60% to $19M, Revenue from contracts with customers increase of 53% to $9.3M. Net Income reflects Impairment of Intangibles Excl. Goodwill decrease from $23M (expense) to $0K.